REFRACTORY HEPATOCELLULAR CARCINOMA
Clinical trials for REFRACTORY HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for young cancer patients: experimental drug targets recurrent tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug duo takes on tough liver cancers
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two immune-boosting drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to prior treatments. About 64 adults will receive the drugs by IV every three weeks. The main…
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC